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Tributyrin, a triglyceride analog of short chain fatty acid butyrate, can act as a prodrug of
an anticancer agent butyrate. In view of other reports that demonstrated the improved
characteristics of conventional liposomes by incorporating small amount of non-
phospholipids such as Tween 80, herein we sought to investigate whether the incorpora-
tion of tributyrin into the liposomal layers may provide additional advantages for
liposomes as an anticancer drug carrier. Liposomes were prepared with dimyr-
istoylphosphatidylcholine as a main phospholipid with or without addition of tributyrin.
Celecoxib was loaded in liposomes as a model anticancer drug. Tween 80-incorporated
liposomes were also prepared for comparison. Tributyrin-incorporated liposomes were
ineffective in enhancing the skin permeation of celecoxib compared to Tween 80-
incorporated ones. However, tributyrin-incorporated liposomes enhanced the entrapped
celecoxib concentration to an extent comparable to Tween 80-incorporated ones.
Furthermore, tributyrin-incorporated liposomes exhibited much higher stability compared
to Tween 80-incorporated ones. Finally, the cellular uptake of celecoxib loaded in
tributyrin-incorporated liposomes into mouse melanoma cells were more than 10-fold
higher compared to that loaded in conventional- and Tween 80-incorporated liposomes.
Taken together, the incorporation of tributyrin into conventional liposomes loaded with
anticancer drugs may provide an advanced anticancer drug carrier delivering both drug
and tributyrin.
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a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 2 8e1 3 3 1291. Introduction improved [15] by incorporation of certain types of substancesHistone deacetylases (HDAC) inhibitors that are effective in
the transcriptional regulation of aberrant gene expression
recently emerged as a potent anticancer agent inhibiting the
development and progression of a wide range of cancer [1].
Butyric acid, a naturally occurring short chain fatty acid pro-
duced by endogenous intestinal bacterial anaerobic fermen-
tation of dietary fibers [2], is one of the most widely studied
HDAC inhibitors. Multiple lines of evidence exist that butyrate
is an effective anticancer agent by alone or in combination
with other anticancer therapy [3,4]. Despite its capability,
butyrate has drawbacks in clinical uses due to its short bio-
logical half-life (6 min) [5,6]. In contrast, tributyrin (TB), a tri-
acylglycerol analog of butyric acid (Fig. 1), can act as a prodrug
after being cleaved by intracellular lipases and esterases into
three molecules of butyric acid [6]. Use of TB was able to
overcome the pharmacokinetic drawbacks of butyrate and TB
exhibited more potent cancer activities compared with buty-
rate [7,8]. Furthermore, TB treatment of cancer cells together
with other anticancer agents was more effective than single
agent treatment, suggesting a carrier delivering both agents
may provide an effective anticancer therapy [9].
Liposomes, colloidal vesicular structures composed of lipid
layers generated when phospholipids are hydrated in an
aqueous media, are one of the most extensively studied drug
carriers [10]. In addition to phospholipids, the basic compo-
nents of liposomal layers, other components are often inser-
ted together in order to provide several advantages as a drug
carrier. For example, insertion of cholesterol was proven to
improve the rigidity of liposomal membranes, thereby
decreasing the leakage of liposomes-entrapped drugs. Inclu-
sion of polyethylene glycol-modified lipids contributed to
interfering the liposome recognition by phagocytic cells, thus
increasing the in vivo half-life of the entrapped substances
[11,12]. Recent studies also show that a modified liposome
formulation composed of phospholipids and nonphospholipid
surfactants exhibit greatly increased skin permeability
compared to the conventional liposomes [13]. It was suggested
that the membrane flexibility and structural deformability of
liposomes were greatly increased due to the existence of
bilayer softening components [10,14]. Similarly, inclusion of
small amount of oleic acid exhibited increased skin perme-
ability of liposomes [14], providing advantage as a transdermal
drug delivery system. The insertion of bile salts in liposomes
greatly increased the liposomal stability in the gastrointes-
tinal tract and enhanced the absorption of liposome-
incorporated drugs [15]. All of these reports demonstrate
that the liposomal characteristics as a drug carrier may beFig. 1 e Chemical structure of TB.in conventional liposomal layers.
Hydrophilic drugs are typically encapsulated within the
aqueous interior of large unilamellar vesicles [16] whereas
hydrophobic drugs are embedded into the phospholipid layers
of multilamellar type vesicles to maximize the drug loading
concentration [17e19]. Therefore, for hydrophilic drugs, the
increase in the volume of aqueous interior may be advanta-
geous to get the enhanced drug loading concentration,
whereas for hydrophobic drugs, the increase in the number of
phospholipid layers may do. In addition to, either widening
the space between phospholipid molecules or between layers
may provide more spaces to load the hydrophobic drugs in
liposomes. In an attempt to investigate a possibility to develop
liposomes containing both of anticancer agent and TB as
a more effective anticancer drug carrier, we sought to
examine whether the incorporation of small amount (<0.6%,
w/v) of TB into liposomal membranes may alter the charac-
teristics of liposomes, including the hydrophobic drug loading
capacity. In view of our previous results that demonstrated
the cooperative anticancer effects by TB and celecoxib
together [9], celecoxib with poor aqueous solubility was
selected as a model drug to be incorporated into liposomes.2. Materials and methods
2.1. Cell lines and cultures
The mouse B16-F10 melanoma cells were purchased from the
Korean Cell Line Bank (Seoul, Korea) andmaintained in DMEM
medium (Welgene, Daegu, Korea), respectively. Each medium
was supplemented with 10% heat inactivated fetal bovine
serum (Hyclone, Logan, UT, USA) and 100 units/mL Penicillin/
streptomycin. Cells were grown in incubators in a humid at-
mosphere of 95% air and 5% CO2.
2.2. Materials
TB and Tween 80 were purchased from SigmaeAldrich Inc
(St. Louis, MO, USA). Celecoxib was obtained from LKT Labo-
ratories (Minneapolis, MN, USA). 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) was purchased from Avanti Polar
Lipids (Alabaster, AL, USA). All other chemicals were of re-
agent grade and used without further purification.
2.3. Preparation of liposomes
Liposomes with or without TB were prepared with a slight
modification from that described in our earlier study [7].
Briefly, 1 mg celecoxib and 24 mg DMPC with or without TB
were first dissolved in t-butyl alcohol. After rapid freezing at
70 C,mixtures were subjected to freeze-drying (EYELA FDU-
1200, Japan). After overnight freeze-drying, the mixture was
suspended in 1 ml of 100 mM phosphate-buffered saline (PBS,
pH 7.4) to produce a multilamellar type liposomes. Liposomes
were briefly vortexed and sonicated in a bath type sonicator
for an hour at 37 C to produce small multilamellar vesicles.
To remove the unentrapped/precipitated celecoxib from
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were immediately filtered through a 0.8 mm membrane filter.
The prepared liposomes were stored at 4 C until use. For
comparison, liposomes composed of DMPC and Tween 80
(24:2, weight ratio) were also prepared.
2.4. Characterization of liposomes
To determine the concentration of celecoxib loaded in lipo-
somes, aliquots of liposome dispersions containing celecoxib
were freeze-dried, redissolved in 1ml of themobile phase and
then filtered through a 0.45 mm membrane filter. The amount
of celecoxib in the resultant clear filtrate was determined by
HPLC analysis as described in the following section.
The mean particle size and polydispersity index (PI) of
liposome dispersions were determined by dynamic light
scattering method using fiber-optics particle analyzer (FPAR-
1000, Otsuka Electronics, Japan). Prior to measurement, dis-
persions were diluted with filtered PBS. The system was used
in the auto-measuring mode. The polydispersity index is a
measure of the uniformity of the droplet size distribution in
colloidal dispersions [20].
The stability of liposomes was evaluated bymonitoring the
changes of mean particle size and PI of celecoxib-loaded li-
posomes during storage at room temperature.
2.5. HPLC analysis of celecoxib
The concentration of celecoxib was analyzed by the HPLC
assay as described in our earlier study [7]. Nanospace SI-2
HPLC system (Shiseido, Japan) equipped with a mobile phase
delivery pump (Model 3201) and a UV-visible detector (Model
3002), was used. The mobile phase was 45:10:45 (v/v/v) mix-
tures of acetonitrile, methanol and distilled water containing
0.2% acetic acid (pH 3.5). The injection volume was 10 ml and
the flow ratewas 1ml/min through a Lichrosorb RP18 reversed
phase column (Phenomenex, Germany). Sample detection
was carried out at 254 nm.
2.6. Skin permeation study
Hairless mice (Dae Han Laboratory Animal Research Com-
pany, Wonju, Korea) were housed and cared for according to
the standards of the Sejong University for animal care and
were used under a protocol approved by the Sejong University
on animal care. After the hairless mouse was sacrificed by
cervical dislocation, the abdominal and dorsal skin was
separated surgically. The skin treated with pen-
icillinestreptomycin for the prevention of skin deterioration
was mounted between the donor and receptor compartments
of a Franz-type vertical diffusion cell with the stratum cor-
neum facing upward. Each cell had a diffusion area of
0.76 cm2. The receptor chamber was filled with about 5 ml of
distilled water containing 4% Tween 80, and was stirred
magnetically in a circulating water bath with a constant
temperature of 37 C to keep the skin surface at approximately
33 C. The skin was equilibrated for 24 h with receptor flowing
while the donor compartment was dry. About 500 ml of each
formulation equivalent to 400 mg of celecoxib were applied
into the donor compartment of each cell non-occlusively. Atappropriate time intervals up to 30 h, 1 ml of samples were
withdrawn from the receptor compartments and replaced by
an equal volume of 4% Tween 80 to maintain the receptor
volume and sink condition. The experiments were carried out
at least in duplicate. Samples were kept at 4 C for a maximum
of 2 days until HPLC analysis was performed as described
above.2.7. Cellular uptake of celecoxib
To investigate the effect of liposome incorporation on the
cellular uptake of celecoxib, the B16-F10 cells were seeded in
100 cm2 dishes and cultured for 24 h to allow the attachment
of cells. Celecoxib-loaded liposome formulations at a dilution
corresponding to 350 mg as celecoxib were added to each dish.
At 2 h post-incubation at 37 C, cells were washed twice with
ice-cold PBS to remove unbound liposomes and collected
using Trypsin. The obtained cell pellet was lysed by using
bioruptor after adding 0.1 ml of 10% sodium dodecyl sulfate.
After centrifugation, an equal volume of acetonitrile was
added to the cell lysate to precipitate the protein, and 20 ml of
supernatant was removed for HPLC analysis. As described
above, the concentration of celecoxib was determined from a
standard curve and normalized to cellular protein content.2.8. Statistical analysis
Statistically significant differences between values obtained
under different experimental conditions were determined
using two-tailed unpaired Student’s t-tests.3. Results and discussion
3.1. Effect of TB incorporation on the celecoxib loading
capacity of liposomes
To minimize a possibility that the phospholipid emulsions
containing TB as an inner oil phase rather than liposomes
containing TB as embedded between phospholipids layers can
be formed by increasing the content of TB, the content of TB to
be added were limited to less than 0.6% of hydration media in
the present study. Incorporation of 0.3% TB increased the
celecoxib concentration loaded in liposomes by 1.8-fold
(Fig. 2). The celecoxib concentration loaded in 0.3% TB-
incorporated liposomes was comparable to that in Tween
80-incorporated liposomes (896  34 vs 937  61 mg). However,
increase in TB content from 0.3 to 0.6% rather decreased the
celecoxib loading concentration (from 896 34 to 833 68 mg).
Although the celecoxib solubility in TB was reported to be
higher than 100 mg/ml in our earlier study [9], it is unlikely
that the increased celecoxib loading in TB-incorporated lipo-
somes is due to the direct solvent effect of TB since no TB dose
dependency was observed. Incorporation of both of TB and
Tween 80 did not further increase the celecoxib loading con-
centration compared to that of TB or Tween 80 alone-
incorporated liposomes. Therefore, it seems likely that TB
incorporation in liposomes affected the loading of celecoxib, a
poorly soluble drug, in an indirect manner.
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Fig. 2 e Effect of TB incorporation on the concentration of
celecoxib loaded in liposomes. The concentration of
celecoxib loaded in liposomes was determined by HPLC
analysis. Significant differences are indicated by asterisks:
*, P< 0.05, **, P< 0.005, compared with conventional
liposomes composed of DMPC alone. Each point represents
the mean ± SD (n [ 3).
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and physical stability of liposomes
When the mean particle size and the polydispersity index of
celecoxib-loaded liposomes were investigated by dynamic
light scattering, it was found that the mean particle size of
0.3% TB-incorporated liposomes was similar to that of con-
ventional liposomes composed of DMPC alone (Table 1).
Tween 80-incorporated liposomes exhibited the smallest
particle size among various liposomal formulations and the
mean particle size of both Tween 80/TB-incorporated lipo-
somes were similar to that of Tween 80-incorporated ones.
These data suggest that the reduction of particle size was
achieved mainly by Tween 80, but not by TB (Table 1). The
polydispersity index of liposomes was lower than 0.3 regard-
less of liposomal composition, indicating the homogeneity of
TB- or Tween 80-incorporated liposomes loaded with cele-
coxib. Togetherwith the celecoxib loading data, it is presumed
that TB was embedded between phospholipid layers, thereby
providingmore spaces where celecoxib, the hydrophobic drug
can occupy.
When liposomes composed of DMPC alone, DMPC/TB,
DMPC/Tween 80 and DMPC/TB/Tween 80 were stored at roomTable 1 e Mean droplet size and polydispersity index of
liposomes prepared with/without incorporation of TB or
Tween 80 (Mean ± SD, n[ 3e4).
Liposome
composition
Mean droplet
size (nm)
Polydispersity
index
DMPC 549  34 0.272  0.081
DMPC/Tween 80 297  26 0.271  0.052
DMPC/TB3 548  22 0.202  0.060
DMPC/Tween 80/TB3 305  22 0.254  0.039temperature up to 42 days, themean particle size of Tween 80-
incorporated liposomes gradually increased to more than
three fold during storage. In contrast, themean particle size of
both of DMPC liposomes and DMPC/TB liposomes remained
unchanged (Fig. 3). The mean particle size of liposomes
composed of DMPC/TB/Tween 80 gradually increased during
storage but the extent was much lower than that of DMPC/
Tween 80 liposomes. Therefore, it appears that the TB incor-
poration into liposomes did not impair the physical stability of
conventional liposomes, whereas the Tween 80 incorporation
did. It has been reported that the surfactant-incorporated li-
posomes, flexible liposomes, are sometimes less stable than
conventional ones due to increase in the membrane fluidity
[10]. Probably the instability of Tween 80-incorporated lipo-
somes is because Tween 80 is an amphiphilic surfactant that
can form other dispersions such as micelles, after being
released from liposomal layers during storage.3.3. Effect of TB incorporation into liposomes on the
celecoxib amount penetrated through excised mouse skin
When the time-dependent changes in the celecoxib con-
centration penetrated through excised mouse skin were
measured during incubation of each liposomal formulation up
to 30 h at 37 C, the concentration of celecoxib permeated
tended to be the highest from DMPC/TB/Tween 80 liposomes,
followed by DMPC/TB liposomes, and the lowest from DMPC/
TB and DMPC liposomes (Fig. 4). Specifically, at 30 h post-in-
cubationwith DMPC/TB/Tween 80, DMPC/Tween 80, DMPC/TB
or DMPC liposomes, 34, 32, 18 and 18 mg celecoxib was pene-
trated through 1 cm2 of skin, respectively. Other studies have
demonstrated the increased transport of entrapped drug from
Tween 80-incorporated liposomes, in consistent with our data
[21]. Therefore, it is concluded that TB incorporation in lipo-
somes is ineffective in enhancing the drug penetration
through skin but does not impair Tween 80-aided transport
(Fig. 4).Days
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Fig. 3 e Effect of TB incorporation on the changes of mean
droplet size of celecoxib-loaded liposomes during storage
at room temperature. Each point represents the mean ± SD
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Fig. 4 e Effect of TB incorporation into liposomes on the
celecoxib amount penetrated through excised mouse skin.
The concentration of celecoxib penetrated through excised
skin was determined by HPLC analysis. Each point
represents the mean ± SD (n [ 2). Significant differences
are indicated by asterisks: *, P< 0.05, **, P< 0.005,
compared with conventional liposomes composed of
DMPC alone.
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Fig. 5 e Effect of TB incorporation into liposomes on the
cellular uptake of celecoxib loaded in various liposomes.
Mouse melanoma B16-F10 cells were incubated with each
liposome for 4 h. The intracellular concentration of
celecoxib taken up by cells was determined by HPLC
analysis. Each point represents the mean ± SD (n [ 2).
Significant differences are indicated by asterisks: *,
P< 0.05, **, P< 0.005, compared with conventional
liposomes composed of DMPC alone.
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celecoxib loaded in liposomes
Liposome formulation that can deliver higher amount of
anticancer drug into cancer cells would be advantageous as an
anticancer drug carrier. To further investigate whether the
cellular uptake of celecoxib can be altered by the composition
of celecoxib-loaded liposomes, the intracellular concentration
of celecoxib was compared at 4 h post-incubation of each
liposome formulation with mouse B16-F10 melanoma cells.
The intracellular concentration of celecoxib after treatment as
DMPC/Tween 80- or DMPC-liposome formulation was less
than 1000 ng/106 cells, suggesting the Tween 80 incorporation
into liposomes was ineffective in increasing the cellular up-
take of celecoxib (Fig. 5.). In contrast, the uptake of celecoxib
loaded in DMPC/TB liposomes was higher than 10,000 ng/
106 cells, indicating the cellular uptake enhancing effect of TB
by more than ten fold compared to conventional liposomes.
The uptake of celecoxib loaded in DMPC/TB/Tween 80 lipo-
somes was approximately 6,400 ng/106 cells. Our data indicate
that TB incorporation into liposomes greatly enhanced the
cellular uptake of liposomes whereas Tween 80 incorporation
was ineffective. Currently, it remains unclear how TB
increased the celecoxib uptake into liposomes. TB is known to
exert HDAC inhibitory activity, thereby regulating multiple
gene expression. The TB concentration added to cells for the
cell uptake experiments was slightly higher than 0.3 mM, a
concentration enough to act as a HDAC inhibitor. However,
since the incubation period was limited to only 2 h, it is un-
likely that the HDAC inhibition by TB already led to the
decrease/increase of protein expression involved in endocy-
tosis. Rather, it is more plausible that TB inclusion between
phospholipids layers of multilamellar vesicles somehowdirectly facilitated the endocytosis of liposomes. For example,
TB might increase the liposomal fluidity, thereby facilitate the
fusion of liposomes with the phospholipids constituting the
plasma membrane. Further studies are warranted.4. Conclusion
Our data demonstrate that small amount of TB incorporation
into liposomes enhanced the entrapped celecoxib concentra-
tion to an extent comparable to Tween 80-incorporated ones.
Furthermore, TB-incorporated liposomes exhibited much
higher stability compared to Tween 80-incorporated ones.
Although TB-incorporated liposomes were ineffective in
enhancing the skin penetration of celecoxib, they increased
the cellular uptake of celecoxib into melanoma cells to a
significantly higher extent compared to conventional- and
Tween 80-incorporated liposomes.
Chemotherapy for cancer patients generally requires
combination of drugs differing in the molecular mechanism
underlying its anticancer effect to enhance the therapeutic
efficacy while minimizing the side effect. TB-incorporated li-
posomes in the present study may provide an advanced
liposomal formulation for the delivery of anticancer drugs and
TB simultaneously.
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